Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799692 | 0.82 | CYP3A4 (0.45) | CYP3A4CYP2D6NPSR1TAAR1SLC6A4 | |
| SCHEMBL1797387 | 0.80 | CYP3A4 (0.44) | CYP3A4CYP2D6GAAMAPTATM | |
| SCHEMBL15304448 | 0.79 | CYP3A4 (0.43) | CYP3A4CYP2D6NPSR1TAAR1SLC6A4 | |
| SCHEMBL2628499 | 0.79 | CYP3A4 (0.43) | CYP3A4CYP2D6NPSR1TAAR1SLC6A4 | |
| Machilin A SCHEMBL10343221 | 0.76 | TAAR1 (0.74) | CYP3A4CYP2D6GAAMAPTATM | |
| Machilin A SCHEMBL30678762 | 0.76 | TAAR1 (0.74) | CYP3A4CYP2D6GAAMAPTATM | |
| Machilin A SCHEMBL31237868 | 0.76 | TAAR1 (0.74) | CYP3A4CYP2D6GAAMAPTATM | |
| SCHEMBL7506672 | 0.74 | CYP3A4 (0.58) | CYP3A4CYP2D6GAAMAPTATM | |
| SCHEMBL31545200 | 0.74 | TAAR1 (0.60) | CYP3A4CYP2D6GAAMAPTATM | |
| SCHEMBL2783585 | 0.73 | CYP3A4 (0.71) | CYP3A4CYP2D6GAAMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | CYP3A4 1411/4885CYP2D6 1388/4885GAA 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.